Image Credit: Courtesy of UCLA
Scientific Frontline: Extended "At a Glance" Summary: AD-NP1 Therapy for Kidney Regeneration
The Core Concept: AD-NP1 is a monoclonal antibody drug developed to promote the repair and regeneration of damaged internal organs by inhibiting a protein that naturally obstructs tissue healing.
Key Distinction/Mechanism: Injured tissues overproduce the ENPP1 protein, which initiates a metabolic cascade that disrupts cellular energy and prevents healthy cell proliferation. AD-NP1 binds exclusively to human ENPP1 and neutralizes it, thereby interrupting these disruptive metabolic signals, reducing scar tissue formation, and allowing renal cells to actively regenerate.
Origin/History: Developed in the laboratory of UCLA cardiovascular scientist Arjun Deb, AD-NP1 was initially engineered and FDA-approved for Phase 1 clinical trials to aid heart tissue repair. A recent study published in Cell Stem Cell demonstrated its successful secondary application in reversing renal damage in mice.
Major Frameworks/Components:
- ENPP1 Protein: An enzyme overexpressed during organ injury that emits metabolic signals impeding tissue regeneration.
- Monoclonal Antibody (AD-NP1): A laboratory-engineered molecule designed to mimic immune system antibodies, formulated specifically to target and inactivate human ENPP1.
- Renal Biomarkers: Measurements of serum creatinine, blood urea nitrogen (BUN), and cystatin C used to quantify renal dysfunction and monitor physiological recovery.
- In Vivo Murine Models: The use of ENPP1-deficient genetic knockouts and wild-type mice with chemically induced kidney damage to validate the metabolic cascade and drug efficacy.
Branch of Science: Regenerative Medicine, Molecular Biology, Cellular Biology, Nephrology, and Pharmacology.
Future Application: Currently entering Phase 1 clinical trials for cardiac applications, researchers plan to pursue further clinical trials to evaluate AD-NP1 as a regenerative treatment for acute kidney injury and chronic kidney disease in humans.
Why It Matters: Common catalysts for kidney damage—including diabetes, sepsis, heart failure, and pharmaceutical toxicity—typically result in permanent scarring and chronic functional decline. Neutralizing ENPP1 offers a novel therapeutic mechanism to actively regenerate tissue and restore organ function, addressing a critical gap in nephrological care.
A drug previously developed at UCLA to help heart tissue repair itself after a heart attack might also help kidney tissue repair and regenerate, researchers have found.
The drug, called AD-NP1, which was recently approved by the FDA for a phase 1 clinical trial in humans, works in heart tissue by blocking a protein that disrupts healing and prevents internal organs from fully recovering. Researchers have now found that blocking this protein in kidney tissue speeds repair after kidney injury in mice.
The new finding, published in Cell Stem Cell, builds upon many years of research in the laboratory of UCLA cardiovascular scientist Arjun Deb.
His group discovered that an injured kidney produces a protein called ENPP1 that initiates a metabolic chain of events, disrupting energy production and the function of multiple cells in the injured region, and impeding tissue repair. The researchers found that blocking ENPP1 enhanced kidney repair and reduced scar tissue formation, thereby improving kidney function. Deb’s group previously determined that blocking ENPP1 in heart tissue improved healing.
Deb’s team examined kidney biopsies from people with chronic kidney disease and found that ENPP1 was expressed at higher levels than in healthy tissue. Next, they fed mice a diet toxic to the kidneys and administered drugs that cause kidney damage to normal mice and ENPP1-knockout mice. Blood tests showed that these mice all had significant increases in serum creatinine, BUN, and cystatin C, which are signs of renal dysfunction. After four weeks, however, these levels were greatly reduced in the mice unable to produce ENPP1 compared with the control mice, indicating that their kidneys were healing.
Having confirmed that blocking the metabolic cascade caused by ENPP1 improved renal repair, the researchers induced kidney damage in normal mice and administered their drug, AD-NP1. Just seven days later, the mice showed improved kidney function, and subsequent inspection of their kidneys revealed less scarring.
“These animals had a far better outcome. Their kidneys were not as damaged, and the kidney cells were proliferating more,” said Deb, who is a UCLA professor of medicine and molecular, cell, and developmental biology, and a member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research. “We found that the same mechanisms we observed in the heart were also applicable in the kidney. After injury, healthy cells around the damaged area were trying to proliferate, but the damaged area was sending metabolic signals that prevented the kidney from regenerating and repairing effectively.”
AD-NP1, which Deb’s group developed entirely at UCLA with public funding, is a monoclonal antibody engineered in the laboratory to mimic the function of natural antibodies produced by our immune system. Just as our immune system can produce specific antibodies to bind and inactivate specific pathogens, the monoclonal antibody AD-NP1 has been engineered to target human ENPP1 and no other human protein.
The drug was approved for phase 1 human clinical trials in September for the heart. Phase 1 trials evaluate the safety, dosing, and metabolism of new drugs and are the first step toward trials assessing their efficacy. Deb plans to apply for trials in the kidneys as well.
Funding: The research was funded by the National Institutes of Health, the California Institute of Regenerative Medicine, and the Department of Defense.
Published in journal: Cell Stem Cell
Title: ENPP1 blockade with a humanized monoclonal antibody enhances renal repair after acute kidney injury
Authors: Lianjiu Su, Qihao Sun, Ziheng Zhou, Rending Wang, Junqiang Wang, Juan Felipe Alvarez, Bo Tao, Kiran Das, Qiuyuan Zhou, Jing Wang, Guanglin Zhang, Johanna ten Hoeve, Linlin Zhang, Calvin Pan, Qiang Du, Hooman Allayee, Zhihao Liu, Ilya Savchenko, Shan Kou, Jijun Wan, Matteo Pellegrini, Aldons J. Lusis, Thomas Graeber, Shen Li, and Arjun Deb
Source/Credit: University of California, Los Angeles | Holly Ober
Edited by: Scientific Frontline
Reference Number: med061626_01
.png)
.jpg)